Draig Therapeutics

Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class therapies for major neuropsychiatric disorders, including Major Depressive Disorder. A Cardiff University spinout co-founded with SV Health Investors, Draig ("dragon" in Welsh) leverages its founders' expertise in modulating the core glutamate/GABA pathways that underlie synaptic excitation and inhibition imbalance in the brain. Its pipeline is led by DT-101, a next-generation AMPA receptor positive allosteric modulator (PAM) advancing toward Phase 2 in MDD, alongside DT-201 and DT-301, subtype-selective GABAA receptor modulators. The company launched from stealth in June 2025 with a $140 million (£107 million) oversubscribed Series A led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital, SV Health Investors, and ICG. Added to the API Evangelist network as a portfolio company of Canaan Partners.

Draig Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Therapeutics, and Neuroscience.

Draig Therapeutics’ developer surface includes support and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

7.1/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-20 · rubric v0.12.0

0 APIs

Company Biotechnology Pharmaceuticals Therapeutics NeuroscienceNeuropsychiatryDrug Discovery Clinical StageCNS

Kin Score

Kin Score How this is scored →
scored 2026-08-20 · rubric v0.12.0

Composite quality — 7.1/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.8 / 17

Access Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.3 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/draig-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 3

The organization behind the API

Website

Website

About

About

LinkedIn

Source (apis.yml)

aid: draig-therapeutics
name: Draig Therapeutics
description: Draig Therapeutics is a clinical-stage biopharmaceutical company developing transformative, best-in-class therapies
  for major neuropsychiatric disorders, including Major Depressive Disorder. A Cardiff University spinout co-founded with
  SV Health Investors, Draig ("dragon" in Welsh) leverages its founders' expertise in modulating the core glutamate/GABA pathways
  that underlie synaptic excitation and inhibition imbalance in the brain. Its pipeline is led by DT-101, a next-generation
  AMPA receptor positive allosteric modulator (PAM) advancing toward Phase 2 in MDD, alongside DT-201 and DT-301, subtype-selective
  GABAA receptor modulators. The company launched from stealth in June 2025 with a $140 million (£107 million) oversubscribed
  Series A led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital,
  SV Health Investors, and ICG. Added to the API Evangelist network as a portfolio company of Canaan Partners.
url: https://raw.githubusercontent.com/api-evangelist/draig-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-industry: Biotechnology
x-headquarters: Cardiff, Wales, United Kingdom
x-tier: profiled
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.23'
created: '2026-07-17'
modified: '2026-07-18'
image: https://draigtherapeutics.com/wp-content/uploads/2026/05/cropped-Draig_favicon-192x192.png
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Therapeutics
- Neuroscience
- Neuropsychiatry
- Drug Discovery
- Clinical Stage
- CNS
apis: []
common:
- type: DomainSecurity
  url: security/draig-therapeutics-domain-security.yml
- type: Website
  url: https://draigtherapeutics.com/
- type: About
  url: https://draigtherapeutics.com/our-approach/
- type: Support
  url: https://draigtherapeutics.com/contact/
- type: PrivacyPolicy
  url: https://draigtherapeutics.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/draigtherapeutics/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence